Yesterday, three pharmaceutical companies released their first-quarter reports, all of which achieved double profits

 On April 20, a number of pharmaceutical companies such as Aibo Medical, Aide Bio, and Asymchem released their 2022 first quarter performance reports
.
According to the report, these three companies have achieved year-on-year growth in operating income and net profit
.
Among them, Aibo Medical's operating income in the first quarter of 2022 increased by 55.
54% year-on-year to 131 million yuan; net profit increased by 63.
00% year-on-year to 58.
6903 million yuan
.
In addition, during the reporting period of Aibo Medical, the total assets at the end of the period were 2.
091 billion yuan, the operating profit was 72.
8199 million yuan, the accounts receivable was 89.
7512 million yuan, and the net cash flow from operating activities was 40.
8705 million yuan.
The cash received from labor services was 121 million yuan
.
The report shows that during the reporting period, the sales volume of Aibo Medical's core products, "Pu Nuo Ming" series of intraocular lenses and "Pu Nuo Tong" orthokeratology lenses, continued to maintain rapid growth, resulting in a year-on-year increase in operating income and net profit attributable to shareholders of listed companies
.
In the first quarter of 2022, the domestic epidemic affected a wide area and a long period of time, resulting in a decrease in the number of cataract and myopia patients visiting doctors, which affected the company's business growth to a certain extent
.
In addition, during the reporting period, the "Punuo Tong-Ximing" multifunctional rigid contact lens care solution developed by Aibo Medical has obtained three types of "Medical Device Registration Certificate" and production license, and is undergoing market promotion
.
Aspheric extended depth of field (EDoF) intraocular lenses are starting clinical trials in China
.
During the reporting period, the epidemic also had a certain impact on R&D work, which delayed some R&D projects
.
In the first quarter of 2022, Aide Bio’s operating income increased by 18.
60% year-on-year to 206 million yuan; net profit increased by 23.
46% year-on-year to 53.
6148 million yuan
.
According to the data, Aide Bio’s main business is the research and development, production and sales of tumor precision medical molecular diagnostic products, and provides related testing services
.
According to the announcement, the total assets of Aide Bio were 1,535,133,046.
49 yuan, an increase of 1.
00% over the end of the previous year; the basic earnings per share was 0.
24 yuan, compared with 0.
2 yuan in the same period last year
.
During the reporting period, sales expenses increased by 42.
82% year-on-year, which was mainly due to the increase in remuneration and marketing expenses for overseas sales staff in the current period
.
During the reporting period, investment income increased by 210.
40% year-on-year, which was mainly due to the increase in income from wealth management products due in the current period
.
In the first quarter of 2022, Asymchem's operating income increased by 165.
28% year-on-year, or about 2.
062 billion yuan; net profit increased by 223.
59% year-on-year, or about 499 million yuan
.
According to public information, Asymchem is an innovative drug API CDMO company and a large-scale commercialization stage chemical drug CDMO company in China
.
Asymchem said that during the reporting period, the strong growth of the company's operating income benefited from the effective promotion of the "two-wheel drive" strategy.
The small molecule business increased by 165.
9% year-on-year, and the emerging business increased by 157.
4% year-on-year.
, preparations, and clinical CRO revenue growth rates all exceeded 100%
.
It is reported that Asymchem has always paid attention to R&D investment.
During the reporting period, Asymchem’s R&D expenses reached 131 million yuan, a year-on-year increase of 56.
86%, accounting for 6.
36% of operating income.
The company continues to increase technological empowerment, develop technological innovation platforms, improve core competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.